

Special Issue

The Era of Vaccines: Advancing Tumor Immunology and Immunotherapy

Message from the Guest Editors

We invite you to submit to our Special Issue titled “The Era of Vaccines: Advancing Tumor Immunology and Immunotherapy”. The complex interactions between the immune system and cancer have become a vital area of study in oncology, leading to significant advancements in tumor immunology and immunotherapy. We seek articles that explore the mechanisms that regulate immune responses within the tumor microenvironment, innovative immunotherapeutic treatments, and translational methods to improve cancer treatment outcomes. The Special Issue will include advancements in neoantigen-based vaccines, dendritic cell vaccines, mRNA vaccines, peptide-based approaches, and combination therapies. We welcome research articles, reviews, and novel methodologies that cover key topics such as cancer vaccines and immunotherapy, tumor immune evasion, immune checkpoint blockade therapy, mechanisms of resistance, CAR-T, T and NK cell therapies, biomarkers, and immunotherapy.

Guest Editors

Dr. Surendra Shukla

Department of Oncology Science, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

Dr. Vinay Kumar

College of Medicine, The Pennsylvania State University Hershey Medical Center, Hershey, PA 17033, USA

Deadline for manuscript submissions

31 January 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/231636

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).